Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Osteopontin: Versatile modulator of liver diseases.

Nagoshi S.

Hepatol Res. 2014 Jan;44(1):22-30. doi: 10.1111/hepr.12166. Epub 2013 Jun 20.

PMID:
23701387
2.

NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.

Syn WK, Agboola KM, Swiderska M, Michelotti GA, Liaskou E, Pang H, Xie G, Philips G, Chan IS, Karaca GF, Pereira Tde A, Chen Y, Mi Z, Kuo PC, Choi SS, Guy CD, Abdelmalek MF, Diehl AM.

Gut. 2012 Sep;61(9):1323-9. doi: 10.1136/gutjnl-2011-301857. Epub 2012 Mar 17.

3.

Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model.

Sahai A, Malladi P, Melin-Aldana H, Green RM, Whitington PF.

Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G264-73. Epub 2004 Mar 25.

4.

Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.

Syn WK, Choi SS, Liaskou E, Karaca GF, Agboola KM, Oo YH, Mi Z, Pereira TA, Zdanowicz M, Malladi P, Chen Y, Moylan C, Jung Y, Bhattacharya SD, Teaberry V, Omenetti A, Abdelmalek MF, Guy CD, Adams DH, Kuo PC, Michelotti GA, Whitington PF, Diehl AM.

Hepatology. 2011 Jan;53(1):106-15. doi: 10.1002/hep.23998. Epub 2010 Oct 21.

5.

Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.

Coombes JD, Choi SS, Swiderska-Syn M, Manka P, Reid DT, Palma E, Briones-Orta MA, Xie G, Younis R, Kitamura N, Della Peruta M, Bitencourt S, Dollé L, Oo YH, Mi Z, Kuo PC, Williams R, Chokshi S, Canbay A, Claridge LC, Eksteen B, Diehl AM, Syn WK.

Biochim Biophys Acta. 2016 Jan;1862(1):135-44. doi: 10.1016/j.bbadis.2015.10.028. Epub 2015 Oct 31.

6.

Role of Osteopontin in Liver Diseases.

Wen Y, Jeong S, Xia Q, Kong X.

Int J Biol Sci. 2016 Aug 6;12(9):1121-8. doi: 10.7150/ijbs.16445. eCollection 2016. Review.

7.

Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin.

Sahai A, Malladi P, Pan X, Paul R, Melin-Aldana H, Green RM, Whitington PF.

Am J Physiol Gastrointest Liver Physiol. 2004 Nov;287(5):G1035-43. Epub 2004 Jul 15.

8.

The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease.

Patouraux S, Bonnafous S, Voican CS, Anty R, Saint-Paul MC, Rosenthal-Allieri MA, Agostini H, Njike M, Barri-Ova N, Naveau S, Le Marchand-Brustel Y, Veillon P, Calès P, Perlemuter G, Tran A, Gual P.

PLoS One. 2012;7(4):e35612. doi: 10.1371/journal.pone.0035612. Epub 2012 Apr 18.

9.

Role of osteopontin in hepatic neutrophil infiltration during alcoholic steatohepatitis.

Apte UM, Banerjee A, McRee R, Wellberg E, Ramaiah SK.

Toxicol Appl Pharmacol. 2005 Aug 22;207(1):25-38.

PMID:
15885730
11.

NF-κB1 deficiency stimulates the progression of non-alcoholic steatohepatitis (NASH) in mice by promoting NKT-cell-mediated responses.

Locatelli I, Sutti S, Vacchiano M, Bozzola C, Albano E.

Clin Sci (Lond). 2013 Feb;124(4):279-87. doi: 10.1042/CS20120289.

PMID:
22970906
12.

Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells.

Kim M, Yang SG, Kim JM, Lee JW, Kim YS, Lee JI.

Int J Mol Med. 2012 Sep;30(3):473-9. doi: 10.3892/ijmm.2012.1029. Epub 2012 Jun 14.

13.
14.

Blockade of IL-6 signaling exacerbates liver injury and suppresses antiapoptotic gene expression in methionine choline-deficient diet-fed db/db mice.

Yamaguchi K, Itoh Y, Yokomizo C, Nishimura T, Niimi T, Umemura A, Fujii H, Okanoue T, Yoshikawa T.

Lab Invest. 2011 Apr;91(4):609-18. doi: 10.1038/labinvest.2011.2. Epub 2011 Feb 14.

15.

Alpha-lipoic acid attenuates methionine choline deficient diet-induced steatohepatitis in C57BL/6 mice.

Min AK, Kim MK, Kim HS, Seo HY, Lee KU, Kim JG, Park KG, Lee IK.

Life Sci. 2012 Jan 30;90(5-6):200-5. doi: 10.1016/j.lfs.2011.11.012. Epub 2011 Dec 1.

PMID:
22154902
16.

Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma.

Zhou C, Zhou HJ, Zhang XF, Lou LL, Ye QH, Zheng Y, Wang J, Zhu HT, Dong QZ, Jia HL, Zhu WW, Guo L, Zhao Y, Gao DM, Qin LX.

Ann Surg Oncol. 2013 Mar;20(3):929-37. doi: 10.1245/s10434-012-2749-9. Epub 2012 Dec 1.

PMID:
23203407
17.

Role of osteopontin and CD44s expression for patients with hepatocellular carcinoma undergoing liver transplantation or resection.

Beckebaum S, Chen X, Sotiropoulos GC, Radtke A, Daoudaki M, Baba HA, Wohlschlaeger J, Broelsch CE, Gerken G, Cicinnati VR.

Transplant Proc. 2008 Nov;40(9):3182-4. doi: 10.1016/j.transproceed.2008.08.034.

PMID:
19010227
18.

Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma.

Zhao J, Lu B, Xu H, Tong X, Wu G, Zhang X, Liang A, Cong W, Dai J, Wang H, Wu M, Guo Y.

Hepatology. 2008 Jul;48(1):265-75. doi: 10.1002/hep.22280.

PMID:
18537194
19.

The temporal expression of osteopontin (SPP-1) in the rodent model of alcoholic steatohepatitis: a potential biomarker.

Banerjee A, Burghardt RC, Johnson GA, White FJ, Ramaiah SK.

Toxicol Pathol. 2006;34(4):373-84.

PMID:
16844665
20.

Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma.

Xie H, Song J, Du R, Liu K, Wang J, Tang H, Bai F, Liang J, Lin T, Liu J, Fan D.

Dig Liver Dis. 2007 Feb;39(2):167-72. Epub 2006 Dec 11.

PMID:
17161983

Supplemental Content

Support Center